Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5843614 | 1.00 | POLB (1.00) | POLBGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23177789 | 1.00 | POLB (1.00) | POLBGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3655855 | 0.91 | POLB (0.83) | POLBGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13806336 | 0.84 | POLB (0.73) | POLBGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29941474 | 0.84 | POLB (0.73) | POLBGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21948970 | 0.83 | POLB (0.71) | POLBGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL926701 | 0.82 | POLB (0.70) | POLBGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4005026 | 0.81 | POLB (0.69) | POLBGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21575851 | 0.80 | POLB (0.67) | POLBGAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21385730 | 0.80 | POLB (0.67) | POLBGAANPSR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | claimed |
| EP-1862181-A2 | Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-12-05 | — | — | EP | claimed |
| EP-1854487-A2 | Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | claimed |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615667-A2 | COMBINATIONS OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| EP-4308628-B1 | ALKYD RESIN, COATING COMPOSITION, AND SUBSTRATE COATED WITH SUCH COATING COMPOSITON | AKZO NOBEL COATINGS INT BV (NL) | 2025-04-30 | — | — | EP | disclosed |
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| EP-1180513-A1 | CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | POLB 1991/4885GAA 778/4885NPSR1 1311/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | POLB 3788/4885GAA 67/4885NPSR1 386/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | POLB 997/4885GAA 1580/4885NPSR1 1183/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | POLB 3788/4885GAA 67/4885NPSR1 386/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | POLB 1025/4885GAA 591/4885NPSR1 2212/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | POLB 1025/4885GAA 591/4885NPSR1 2212/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | POLB 997/4885GAA 1580/4885NPSR1 1183/4885 |
| US-20060111366-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | POLB 1991/4885GAA 778/4885NPSR1 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.